Guided Therapeutics (GTHP) Short term Debt (2011 - 2024)

Guided Therapeutics has disclosed Short term Debt across 14 years of filings, most recently posting $1.1 million for Q3 2024.

• In Q3 2024, Short term Debt changed N/A year-over-year to $1.1 million; the TTM figure through Sep 2024 stood at $1.1 million (changed N/A YoY), while the FY2022 annual figure was $17000.0, down 80.68% from the prior year.
• Short term Debt came in at $1.1 million for Q3 2024 at Guided Therapeutics, roughly flat from $1.1 million in the prior quarter.
• In the past five years, Short term Debt ranged from a high of $1.1 million in Q2 2024 to a low of $17000.0 in Q4 2022.
• Average Short term Debt over 5 years is $256133.3, with a median of $116000.0 recorded in 2020.
• Year-over-year, Short term Debt surged 146.4% in 2021 and tumbled 80.68% in 2022.
• Over 5 years, Short term Debt stood at $328000.0 in 2020, then tumbled by 73.17% to $88000.0 in 2021, then sank by 80.68% to $17000.0 in 2022, then soared by 70.59% to $29000.0 in 2023, then soared by 3796.55% to $1.1 million in 2024.
• Per Business Quant data, the three most recent Short term Debt figures were $1.1 million in Q3 2024, $1.1 million in Q2 2024, and $29000.0 in Q1 2023.